944896-42-8

Basic information

• Product Name: 6-Bromoimidazo[1,2-a]pyridine-3-carboxylicacid
• Synonyms: 6-Bromoimidazo[1,2-a]pyridine-3-carboxylicacid;IMidazo[1,2-a]pyridine-3-carboxylic acid, 6-broMo-;6-Bromo-3-carboxyimidazo[1,2-a]pyridine
• CAS NO: 944896-42-8
• Molecular Formula: C₈H₅BrN₂O₂
• Molecular Weight: 241.044
• Mol File: 944896-42-8.mol

Chemical Properties

• Appearance: /
• Density: 1.899 g/cm³
• Refractive Index: 1.728
• Storage Temp.: 2-8°C
• PKA: -0.99±0.41(Predicted)
• CAS DataBase Reference: 6-Bromoimidazo[1,2-a]pyridine-3-carboxylicacid(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Bromoimidazo[1,2-a]pyridine-3-carboxylicacid(944896-42-8)
• EPA Substance Registry System: 6-Bromoimidazo[1,2-a]pyridine-3-carboxylicacid(944896-42-8)

Safety Data

• Hazardous Substances Data: 944896-42-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
6-Bromoimidazo[1,2-a]pyridine-3-carboxylic acid is used as a pharmaceutical intermediate for the synthesis of various drugs and drug candidates. Its heterocyclic nature allows for the development of compounds with diverse biological activities, making it a valuable building block in medicinal chemistry.
As a pharmaceutical intermediate, 6-Bromoimidazo[1,2-a]pyridine-3-carboxylic acid can be utilized in the design and synthesis of new drugs targeting a wide range of therapeutic areas. Its unique structure can be further modified through chemical reactions to create derivatives with specific pharmacological properties, enhancing its potential as a versatile compound in drug discovery and development.

InChI:InChI=1/C8H5BrN2O2/c9-5-1-2-7-10-3-6(8(12)13)11(7)4-5/h1-4H,(H,12,13)

Upstream product

• 138240-34-3 (E)-N’-(5-bromopyridin-2-yl)-N,N-dimethylformamidine 
• 1359656-01-1 methyl 6-bromoimidazo[1,2-a]pyridine-3-carboxylate 
• 138888-98-9 N’-(5-bromopyridin-2-yl)-N,N-dimethylformimidamide 
• 474708-98-0 6-bromoimidazo[1,2-a]pyridine-3-carbonitrile 
• 1072-97-5 5-bromo-2-pyridylamine 
• 33142-21-1 ethyl 2-chloro-3-oxopropanoate 
• 372198-69-1 ethyl 6-bromoimidazol[1,2-a]pyridine-3-carboxylate 

Downstream Products

• 1296201-66-5 6-bromo-N-(3-methoxybenzyl)imidazo[1,2-a]pyridine-3-carboxamide 
• 474708-98-0 6-bromoimidazo[1,2-a]pyridine-3-carbonitrile 
• 2044706-79-6 6-bromoimidazo[1,2-a]pyridine-3-carboxamide 
• 1426530-97-3 N-(5-(2-tert-butoxyethylcarbamoyl)-2-fluorophenyl)-7-(6-(3-(dimethylamino)propoxy)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carboxamide 
• 1426671-16-0 6-bromo-N-(2-methyl-5-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)imidazo[1,2-a]pyridine-3-carboxamide 
• 1268454-23-4 (6-(2-aminobenzo[d]oxazol-5-yl)imidazo[1,2-a]pyridin-3-yl)(morpholino)methanone 
• 1426449-72-0 6-bromo-N-(5-(5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl)-2-methylphenyl)imidazo[1,2-a]pyridine-3-carboxamide 
• 1426448-87-4 N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-6-[(2R,6S)-2,6-dimethylmorpholin-4-yl]imidazo[1,2-a]pyridine-3-carboxamide 
• 1426448-31-8 N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-6-(1H-pyrazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide 

Relevant articles and documents

Discovery of 3,6-disubstutited-imidazo[1,2-a]pyridine derivatives as a new class of CLK1 inhibitors

Inhibition of cdc2-like kinase1 (CLK1) could efficiently induce autophagy and it has been thought as a potential target for treatment of autophagy-related diseases. Herein we report the discovery of a series of 3,6-disubstutited-imidazo[1,2-a]pyridine derivatives as a new class of CLK1 inhibitors. Among them, compound 9e is the most potent one, which exhibits an IC50 value of 4 nM against CLK1 kinase. In vitro, this compound reduces the phosphorylation level of the typical downstream substrates of CLK1 and affects their subcellular redistribution. Further study indicates that 9e is efficient to induce autophagy. Overall, this study provides a promising lead compound for drug discovery targeting CLK1 kinase.

Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof

The present invention provides for a method for treating a disease condition associated with PI3-kinase α and/or mTOR in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase α and/or mTOR in a subject. In yet another aspect, a method of inhibiting phosphorylation of both Akt (S473) and Akt (T308) in a cell is set forth.

2,3-DISUBSTITUTED PYRIDINE COMPOUNDS AS TGF-BETA INHIBITORS AND METHODS OF USE

The invention described herein comprises compounds of formula (IV) and a method of treating cancer comprising administering to a subject having cancer one of the compounds in conjunction with another therapeutic treatment of cancer. The compounds (IV) inhibit signaling by a member of the TGF-β superfamily such as Nodal or Activin.

COMBINATION OF KINASE INHIBITORS AND USES THEREOF

The present invention provides for a method for treating a disease condition associated with PI3-kinase a and/or a receptor tyrosine kinase (RTK) in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase α and/or an RTK in a subject. In yet another aspect, a method of inhibiting phosphorylation of Akt (S473) in a cell is set forth.

(1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV

The invention relates to an administration unit comprising a compound of formula and/or pharmaceutically acceptable salts thereof, and to a packaging comprising the administration unit according to the invention.

COMBINATION OF KINASE INHIBITORS AND USES THEREOF

The present invention provides for a method for treating a disease condition associated with PI3-kinase a and/or mTOR in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase a and/or mTOR in a subject. In yet another aspect, a method of inhibiting phosphorylation of both Akt (S473) and Akt (T308) in a cell is set forth. The present invention also provides a pharmaceutical kit effective for treating a disease condition associated with PI3 -kinase α and/or mTOR in a subject.

COMPOUNDS AND COMPOSITIONS AS PDGFR KINASE INHIBITORS

The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase

COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS

The invention provides compounds of formulae (I) and (II) and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit and PDGFR (PDGFRcalpha PDGFRbeta) kinases

KINASE INHIBITOR POLYMORPHS

Polymorphs of chemical compounds that modulate kinase activity, including PI3K activity, and chemical compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3K activity, are described herein.

BICYCLIC HETEROARYLS AS KINASE INHIBITORS

The invention is directed to heteroaryl compounds useful as inhibitors of various kinase enzymes. In various embodiments, the invention provides a heteroaryl compound having inhibitory bioactivity with respect to a Rho kinase, an AKT kinase, a p70S6K kinase, a LIM kinase, an IKK kinase, a Flt kinase, an Aurora kinase, or a Src kinase, or any combination thereof. Compounds of the invention include bicyclic heteroaryl compounds of formula (I), which can contain a bridging nitrogen atom at a ring junction. The invention further provides methods of synthesis of compounds of the invention, pharmaceutical compositions, pharmaceutical combinations, and methods of treatment of malconditions using compounds of the invention.